Potential Role of Seleno-LMethionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study)

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution

Pembrolizumab (pembro) vs placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study

MK-1308A + lenvatinib and pembrolizumab + belzutifan + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for clear cell renal cell carcinoma: randomized, open-label, phase 3 study

Pembrolizumab with lenvatinib in the first-line setting for non–clear cell renal cell carcinoma: Openlabel, phase 2 KEYNOTE-B61 study

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)

Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma

Phase II trial of Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)

ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations

Randomized, open-label, phase 3 study of belzutifan plus lenvatinib versus cabozantinib in patients with advanced renal cell carcinoma after anti–PD-1/PD-L1 therapy

Treatment of advanced renal cell carcinoma after progression on systemic therapy: An open-label phase 2 study of 2 doses of the HIF-2α inhibitor belzutifan

A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment